With the FDA's approval as expected of Rockwell Medical Inc.'s iron-replacement drug Triferic (soluble ferric pyrophosphate), the talk turned to sales forecasts, and the Wixom, Mich.-based company's optimism was called into question by Brean Capital Markets LLC analyst Jonathan Aschoff, who characterized as "dismal" the compound's prospects.